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Tuberculosis remains a major source of morbidity
and mortality worldwide, with 10 million cases and
1.5 million deaths in 2018. Achieving ‘End TB’
prevention and care goals by 2035 will likely
require a new tuberculosis vaccine. The tubercu-
losis vaccine development pipeline has seen
encouraging progress; however, questions around
their population impact and implementation
remain. Mathematical modelling investigates these
questions to inform vaccine development and
deployment strategies. We provide an update on
the current vaccine development pipeline, and a
systematic literature review of mathematical mod-
elling of the epidemiological impact of new tuber-
culosis vaccines. Fourteen prophylactic
tuberculosis vaccine candidates are currently in
clinical trials. Two candidates have shown promise
in phase II proof-of-concept efficacy trials: M72/
AS01E demonstrated 49.7% (95% CI; 2.1, 74.2)
protection against tuberculosis disease, and BCG
revaccination demonstrated 45.4% (95% CI; 6.4,
68.1) protection against sustained Mycobacterium
tuberculosis infection. Since the last modelling
review, new studies have investigated the epidemi-
ological impact of differential vaccine characteris-
tics, age targeting and spatial/risk group targeting.
Critical research priorities for M72/AS01E include
completing the currently in-design trial, powered to
improve the precision of efficacy estimates, include
uninfected populations and further assess safety
and immunogenicity in HIV-infected people. For
BCG revaccination, the priority is completing the
ongoing confirmation of efficacy trial. Critical mod-
elling gaps remain on the full value proposition of
vaccines, comparisons with other interventions
and more realistic implementation strategies.
Using carefully designed trials and modelling, we
must prepare for success, to ensure that new
vaccines will be promptly received by those most
in need.
Keywords: clinical trial, mathematical model, sys-
tematic review, tuberculosis, vaccine.
Introduction
Tuberculosis (TB) was the leading cause of death
due to a single infectious pathogen worldwide in
2018, with an estimated 10 million new cases and
approximately 1.5 million deaths [1]. Over two-
thirds of cases are found amongst eight countries:
India, China, Indonesia, the Philippines, Pakistan,
Nigeria, Bangladesh and South Africa. Global TB
control efforts are hindered by the emergent epi-
demic of drug-resistant tuberculosis.
Approximately 500 000 cases of rifampicin-resis-
tant tuberculosis (RR-TB) arose in 2018, of which
78% were multi-drug-resistant tuberculosis (MDR-
TB).
The global community has set ambitious TB con-
trol and elimination targets. The World Health
Organization (WHO) End TB Strategy defines mile-
stones and targets for TB control by 2035, which
aim to reduce TB deaths by 95% and incidence by
90% compared with 2015 [2]. Despite these goals,
progress has been slow. TB incidence declined only
1.6% per year between 2000 and 2018, and TB
deaths declined 11% between 2015 and 2018. To
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Review Symposium
affirm its commitment to TB control, in 2019, the
UN General Assembly issued a political declaration
following the first-ever high-level meeting on TB,
which included targets to mobilize at least USD 13
billion towards TB diagnosis, care and prevention
by 2022, and at least USD 2 billion towards TB
research.
The End TB Strategy recognizes that a lack of
optimal tools to prevent TB, including a vaccine, is
a key barrier for TB control, and calls for intensified
research and innovation in this area. Encourag-
ingly, the TB vaccine pipeline has recently seen
rapid development. There are prophylactic vaccine
candidates at all stages along the clinical develop-
ment pathway [3,4], including three in phase I,
eight in phase II and three in phase III, reflecting a
diverse array of antigens and proposed mecha-
nisms of vaccine effect. Two recent phase II efficacy
trials have reported promising results. A trial of
adolescent bacille Calmette–Guérin (BCG) revacci-
nation in South Africa demonstrated 45.4% reduc-
tion in sustained Mycobacterium tuberculosis (Mtb)
infection [5]. A trial of the new TB vaccine candi-
date M72/AS01E in adults reported 49.7% efficacy
in preventing TB disease at 3 years of follow-up [6].
Given their likely integral role in TB elimination, we
review the current state of clinical development of
TB vaccines. In the following sections, we provide a
general classification of TB vaccines and review the
current candidates along the TB vaccine clinical
development pathway. We summarize the mathe-
matical modelling literature used to inform vaccine
development, focusing on models that address the
epidemiologic impact of new TB vaccines. Finally,
we describe the future for TB vaccines in the effort
towards TB elimination.
Classification of tuberculosis vaccines
Besides conventional characteristics such as the
duration of protection and vaccine efficacy, we
classify prophylactic TB vaccines along the two
major qualitative axes: (a) the host infection status
required for efficacy and (b) the mechanism of
effect (Figure 1).
The host infection status required for efficacy is
defined relative to the tuberculosis natural history
state of the vaccine recipient in which the vaccine
is effective. Vaccines effective only in individuals
who are not infected by Mtb are referred to as
‘preinfection’ (PRI) vaccines (sometimes referred to
as ‘pre-exposure’ vaccines). In contrast, vaccines
effective in individuals who either have current
latent infection or have recovered from disease
(through treatment or through natural cure) are
referred to as ‘postinfection’ (PSI) vaccines (some-
times referred to as ‘postexposure’ vaccines). Vac-
cines effective in uninfected, latent and recovered
individuals are known as ‘pre- and postinfection’
vaccines (P&PI). Therapeutic vaccines, which mod-
ify disease in those with active tuberculosis, are not
considered in this review.
We classify the mechanism of effect as the point
along the progression from infection with Mtb to
the development of active tuberculosis disease at
which the vaccine exerts its effect. A prevention of
infection (POI) vaccine reduces the probability of
infection by Mtb. In contrast, the probability of
infection is unaffected directly by a prevention of
disease (POD) vaccine. POD vaccines act through
one or more of (a) reducing the rate of progression
to active disease following infection or reinfection
with Mtb (‘fast progression’); (b) reducing the rate of
reactivation from latent infection to active disease;
and/or (c) reducing the rate of relapse from recov-
ered to active disease.
Candidates in clinical trials
The need for new TB vaccines and challenges in development
Infant BCG vaccination protects against severe
extrapulmonary forms of TB in young children and
is an important mainstay of national immunization
programmes in TB endemic countries. However,
BCG is contraindicated in HIV-positive individuals,
an epidemiologically important population, due to
an increased risk of disseminated BCGosis. Addi-
tionally, estimates of BCG efficacy against adoles-
cent and adult pulmonary TB vary, ranging from
an ‘absence of clinically important benefit’ in
Malawi and India, to almost 80% protection in the
UK and a North American Indigenous population
[7–9]. Vaccines effective against pulmonary TB in
adolescents and adults, but also in the elderly, and
that are safe and effective in latently infected
individuals and HIV-positive individuals are
urgently needed.
The major impediment to new TB vaccine develop-
ment is the lack of a correlate of protection, which
necessitates large, long and expensive trials to
demonstrate prophylactic efficacy against TB dis-
ease. The relatively low incidence of TB implies that
adequately powered phase III trials will typically
require at least 10 000 participants and cost in the
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order of USD 100 million or more. Until a correlate
of protection exists to allow immunobridging, effi-
cacy trials may be necessary for extending regis-
tration to important populations other than those
in the initial licensure trial, including HIV-positive
populations, other age groups and other geogra-
phies. Short, inexpensive challenge studies are not
yet an option in TB, as unlike malaria or influenza
where quick, safe and effective treatments are
available, TB treatment lasts at least 6 months
and carries a risk of drug resistance.
Progress and innovation in clinical trials
Despite these challenges, the current TB vaccine
candidate development pipeline is the strongest to
date. Fourteen vaccine candidates (Figure 2) are in
clinical development, including seven entering or
Fig. 1 Tuberculosis vaccine mechanism of effect and host infection status required for efficacy. Mechanism of effect is
indicated by double bars along natural history pathways. Host infection status required for efficacy is indicated by
background colour.
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already in proof-of-concept or full efficacy trials.
The pipeline includes vaccines using viral vectors,
live attenuated Mtb, inactivated whole cell and
protein/adjuvant technologies.
Alongside the classical phase I/II/III trials, phase
IIB (proof-of-concept) trials have been used to
provide an initial assessment of efficacy for new
TB vaccine candidates. These are valuable in stage-
gating and de-risking the TB pipeline before the
more substantive investment of a phase III trial.
Studies in adults have historically focused on
pulmonary disease as their outcome. Now, driven
by the need for earlier indications of efficacy and
de-risking of phase III investment, proof-of-concept
trials may investigate infection or recurrence out-
comes. Rates of infection and recurrence are
greater than primary disease, so can help minimize
trial size, as can recruiting other high-risk popu-
lations such as household contacts and healthcare
workers. Furthermore, modelling has demon-
strated the important contribution of reactivation
and relapse to disease burden in many settings,
leading to increased recognition of the need to
protect postinfection (latently infected or recovered)
populations [10–12]. Therefore, increasingly, stud-
ies either include or exclusively recruit postinfec-
tion populations.
We summarize the status of pipeline candidates in




The early TB vaccine candidate pipeline is cur-
rently focused on new approaches to vaccine
delivery (e.g. aerosolized, intranasal).
Two adenovirus-vectored candidates based on the
mycobacterial antigen 85A are currently in sepa-
rate phase I trials: Ad5-Ag85A [13] and ChA-
dOx185A-MVA85A prime-boost [14]. Both trials
aim to investigate the safety and immunogenicity of
aerosolized compared with intramuscular delivery
Fig. 2 Classification of tuberculosis vaccines by trial phase, trial outcome (POI or POD) and population where vaccines
were tested for efficacy (PSI, PRI or P&PI). The phase and trial outcome are based on the latest ongoing or completed clinical
trials per candidate. POI and POD trial outcomes are only applicable to proof-of-concept or efficacy trials. H56:IC31 is under
investigation for prevention of recurrent disease effect. VPM1002 is under investigation for both prevention of primary and
recurrent disease effects. The host infection status required for efficacy reflects the various populations the candidate has
been or is being trialled in for efficacy.
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in BCG-vaccinated adults. The ongoing phase I
trial for Ad5-Ag85A, developed by McMaster
University, follows IGRA-negative adults for
24 weeks postadministration. The ongoing phase
I trial for ChAdOx185A-MVA85A, developed at
Oxford University, is following 39 IGRA-negative
participants for 168 days and is expected to com-
plete in late 2020. A phase IB/IIA trial for dose
ranging and age de-escalation is ongoing in
Uganda, with completion expected in 2022 [15],
focusing on intramuscular administration.
AEC/BC02, developed by Anhui Zhifei Longcom,
China, is a whole-cell freeze-dried Mtb vaccine
delivered in six intramuscular doses. A nonrandom-
ized open-label placebo-controlled phase I trial
recruiting 135 adults (18–45 years old) with varying
host infection status was completed in 2019, but
results are unpublished at the time of writing [16].
Phase IIA
Four candidates have recently completed or are
currently in phase IIA trials: TB/FLU-04L, GAMTB-
Vac, MTBVAC and ID93 + GLA-SE.
TB/FLU-04L comprises a recombinant replication-
deficient influenza virus A expressing mycobacte-
rial antigen ESAT-6, developed by Research Insti-
tute of Influenza, St Petersburg [17]. A randomized
open-label phase I trial of intranasal or sublingual
vaccine administration in 36 IGRA-negative 18- to
50-year-olds has demonstrated safety and tolera-
bility [18]. A phase IIA trial in IGRA-positive
individuals is being implemented.
GAMTBVac, a subunit recombinant vaccine con-
taining mycobacterial antigens 85A and ESAT-
CFP10, developed by the Gamaleya Research Insti-
tute of Epidemiology and Microbiology, Russia,
demonstrated safety and underwent dose selection
inphase I. Anongoing phase IIA trial to assess safety
and immunogenicity (measured as interferon-
gammaresponse) inBCG-vaccinated IGRA-negative
adults is expected to be completed in 2020 [19].
In a randomized, double-blind controlled phase IIA
trial, MTBVAC (live attenuated Mycobacterium
tuberculosis) was found to have a similar safety
and reactogenicity profile to BCG in infants, and a
specific and durable immune response up to one
year [20,21]. Two further phase IB/IIA safety and
immunogenicity and dose-finding trials are cur-
rently recruiting in South Africa, in infants [22] and
in adults [23].
Ongoing or upcoming trials of ID93 + GLA-SE (a
recombinant protein comprising four Mtb antigens,
combined with adjuvant GLA-SE) span phases I to
IIA. Safety and age de-escalation has been demon-
strated in a South Korean BCG-vaccinated IGRA-
negative adolescent phase I trial [24]. Phase IIA
demonstrated safety and immunogenicity in 60
adults (aged 18–60 years) with a history of previ-
ous treatment for drug-sensitive tuberculosis [25].
A phase IIA trial of 107 BCG-vaccinated IGRA-
negative South Korean healthcare workers is ongo-
ing, with expected completion in 2020 [26]. A phase
IIB study of 1000 BCG-vaccinated adolescents and
adults in South Korea, China, Indonesia, the
Philippines and Thailand is planned [4].
Phase IIB
There are four candidates that have recently com-
pleted or are currently undergoing phase IIB proof-
of-concept efficacy trials: H56:IC31, DAR-901,
BCG revaccination and M72/AS01E.
H56:IC31, a fusion protein of mycobacterial anti-
gens 85B, ESAT-6 and Rv2660c with IC31 adju-
vant, is currently in a phase IIB trial expected to
report in 2022. The study is recruiting 900 HIV-
negative adults who have been successfully treated
for drug-sensitive tuberculosis [27], with primary
end-point of culture-positive recurrent TB disease
within 12 months after a second vaccination.
Since the introduction of BCG, only a single new
vaccine candidate, SRL-172 (an inactivated whole
cell booster derived from non-tuberculous myco-
bacterium), has demonstrated safety and efficacy in
a phase III trial. However, the agar based manufac-
turing process couldnot be scaled. A candidate from
the samemaster cell bank,DAR-901,has sincebeen
adapted for broth-based production, and recently
completed a phase IIb trial [28,29]. This study
measured the prevention of Mtb infection in 667
BCG-vaccinated, HIV-negative and IGRA-negative
Tanzanian adolescents. A three-dose series of DAR-
901 was safe and well-tolerated, but did not show
any differences in either primary (IGRA conversion)
or secondary (sustained IGRA conversion) end-
points [30]. [Correction added on 22 January
2021, after first online publication: this paragraph
has been amended.]
Given that the historical literature suggests uncer-
tain BCG efficacy for preventing disease in adults
and adolescents, the use of BCG revaccination has
been largely discontinued and remains
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implemented in only nine countries. However,
questions regarding the value of BCG revaccination
to protect Mtb-uninfected individuals at high risk
of Mtb infection have resurfaced following a three-
arm randomized controlled trial recruiting IGRA-
negative, neonatally BCG-vaccinated adolescents
in South Africa, which compared the efficacy of the
new H4:IC31 vaccine candidate or BCG revaccina-
tion against a placebo [5]. H4:IC31 did not meet the
primary efficacy end-point for the prevention of
infection (POI vaccine efficacy: 9.4%, P = 0.63),
and development was discontinued. However, BCG
revaccination did meet the secondary end-point of
prevention of sustained infection compared with
placebo. Efficacy, measured by sustained IGRA
conversion for 6 months, was 45.4% (95% CI; 6.4,
68.1) [5]. As the trial was not primarily designed to
study this end-point, a larger trial is required to
further investigate this result. A BCG revaccination
trial of 1800 BCG-vaccinated IGRA-negative chil-
dren and adolescents (age 10–18) has been initi-
ated in South Africa, with a primary outcome of
prevention of sustained IGRA conversion at 3 and
6 months [31]. Results are anticipated in 2025.
Further studies are likely to be needed to investi-
gate whether sustained IGRA conversion translates
into prevention of TB disease.
The M72/AS01E vaccine was the first protein-adju-
vant vaccine to demonstrate efficacy against TB
disease. The vaccine consists of the M72 antigen
(recombinant fusion of Mtb32A and Mtb39A) and
the liposome-based AS01E adjuvant. The phase IIB
proof-of-concept randomized, double-blinded, pla-
cebo-controlled study enrolled 3575 IGRA-positive
HIV-negative adults aged 18–50 years in Kenya,
South Africa and Zambia. The primary outcomewas
bacteriological confirmation of pulmonary tubercu-
losis, in HIV-negative individuals and sampled
before initiation of any treatment. According to this
primary case definition, the interim analysis at two
years of follow-up demonstrated a vaccine efficacy
of 54% (95% CI; 2.9, 78.2). In the final analysis,
protection was sustained through to three years of
follow-up with overall vaccine efficacy of 49.7%
(95% CI; 2.1, 74.2) [6]. Furthermore, a sensitivity
analysis on this primary end-point applying a more
stringent case definition requiring two bacteriolog-
ically positive tests indicated vaccine efficacy of
68.0% (95% CI; 25.1, 86.3). The study also demon-
strated a good safety profile and highly persistent
humoral and poly-positive cellular responses. The
encouraging results of this vaccine andnext steps in
development were the subject of two World Health
Organization consultations in 2019 [32,33]. Con-
sensus was generated around other priority popu-
lations requiring further safety and/or efficacy
data, including IGRA-negative populations, HIV-
positive populations, age escalation (>50 years),
age de-escalation, broader geography and pregnant
women. Two pathways to registration were consid-
ered: a traditional multi-country phase III or single-
country accelerated licensure based upon the exist-
ing phase IIB data. The accelerated pathway could
theoretically achieve first licensure by 2022 but
would likely be for amuch-restricted indication (e.g.
HIV-uninfected, LTBI-positive individuals in South
Africa). This would likely lead to subsequent chal-
lenges generalizing to other countries, as conduct-
ing further placebo-controlled trials once there is no
longer equipoise may be deemed unethical. The
traditional pathway could ensure broader indica-
tion and generalizability but would likely delay
initial registration by at least 4–5 years. In January
2020,M72/AS01Ewas licensed byGSK to theGates
Medical Research Institute (GMRI). Technology
transfer to GMRI and development of a large safety
study in people living with HIV and planning of the
phase III trial are underway.
Phase III
Three candidates have recently completed or are
currently undergoing phase III trials: M.vaccae,
VPM1002 and Immunovac/MIP.
M.vaccae (a heat-killed preparation of Mycobac-
terium vaccae, developed by Anhui Zhifei Longcom)
is already licensed as adjunctive immunotherapy
for the treatment of active tuberculosis in China. A
phase III efficacy trial of a six-dose regimen inves-
tigating prevention of disease in 10,000 individuals
with LTBI has been completed [34], and publica-
tion of the results is anticipated.
VPM1002 (recombinant BCG modified to improve
immunogenicity, developed by the Max Planck
Institute of Infection Biology and licensed through
Vakzine Projekt Management to Serum Institute of
India) has demonstrated safety and immunogenic-
ity in phase I [35]. In an open-label randomized
phase IIA trial in Cape Town, VPM1002 has shown
safety, tolerability and immunogenicity in 48 HIV-
unexposed newborns [36]. A phase IIB in HIV-
exposed newborns is ongoing [37]. A phase II/III
trial to investigate prevention of recurrence in 2000
participants who have successfully completed
treatment for drug-sensitive tuberculosis is under-
way in India and expected to complete in 2020 [38].
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A 12 000-participant three-arm multi-centre ran-
domized placebo-controlled phase III trial to assess
the ability of VPM1002 or Immunovac/MIP (below)
for preventing disease in household contacts of
patients diagnosed with sputum-positive pul-
monary TB is underway in India [39].
Immunovac/MIP (heat-killed Mycobacterium indi-
cus pranii, a nonpathogenic nontuberculous
mycobacterium, produced by Cadila Pharma) has
been reported to demonstrate safety and efficacy as
an adjunctive therapy for pulmonary TB [40,41],
but to our knowledge is being investigated as a
prophylactic TB vaccine for the first time.
The potential impact of COVID-19 on TB vaccine
trials
The COVID-19 pandemic is likely to have implica-
tions for TB vaccine trials. First, trials are likely to
be disrupted, halted or delayed, leading to lower
recruitment, ability to conduct follow-up visits and
altered participant care seeking behaviour. At the
time of writing, the phase IIB BCG revaccination
confirmatory trial is on hold. Other trials due to
start may also be delayed.
Second, COVID-19 may affect TB incidence in
study populations through two opposing influ-
ences: social distancing and reduced access to
care [42,43]. If social distancing reduces Mtb
transmission, this may reduce end-point accrual,
particularly infection outcomes, and potentially
disease outcomes. If access to TB care is reduced,
transmission and severity could increase. Prelim-
inary mathematical models suggest that increased
social distancing may reduce TB incidence in some
settings, with minimal impact on TB deaths, which
were found to increase substantially with disrup-
tion to TB care [42]. Finally, it is unknown whether
COVID-TB coinfection interacts to alter the rate or
severity of TB cases.
Conversely, TB vaccine development may benefit
from scientific developments due to COVID-19,
and vice versa. Importantly, it may be possible to
leverage clinical trial sites from COVID-19 site
mapping initiatives, and technological develop-
ments for remote data collection and digital health
monitoring may provide valuable tools to facilitate
follow-up in future TB vaccine trials. Public and
governmental perception of the value of vaccines
has also increased during the pandemic, which
may positively affect TB vaccine acceptance and
funding.
Summary of pipeline
The current prophylactic TB vaccine pipeline is
diverse, with candidates across all phases of
trials. Recent positive phase II efficacy results
have shifted focus towards adolescent and adult
TB vaccines. Several phase III trials are planned,
including investigating prevention of disease end-
points. TB vaccine trial design has also evolved,
shifting from demonstrating prevention of disease
in infants, towards more studies assessing pre-
vention of infection, disease or recurrence in
adolescents and adults, including in proof-of-
concept studies to de-risk progression to phase
III.
Mathematical modelling of tuberculosis vaccines
Other than for BCG, the real-world efficacy of the
vaccine candidates discussed above has not yet
been established. Questions around their likely
population-level impact, targeting, delivery strat-
egy and cost-effectiveness remain, which mathe-
matical modelling aims to address by leveraging
empirical data, expert input and scenario analyses.
In 2016, Harris et al [44] published a systematic
review of the tuberculosis vaccine modelling liter-
ature evaluating the body of knowledge on the
epidemiological impact of future TB vaccines. Here,
we briefly summarize this systematic review and
update the systematic searches to reflect the latest
developments in TB vaccine modelling.
Systematically reviewed literature to date
The original systematic review identified 23 studies
modelling the epidemiological impact of new TB
vaccines [44]. These were summarized based on
their proposed vaccine characteristics, implemen-
tation setting and epidemiological impacts.
The review found that most studies modelled
prevention of disease (POD) or prevention of infec-
tion (POI) vaccines in a preinfection (PRI) popula-
tion, or a POD vaccine in a postinfection (PSI)
population. Whilst no clear consensus was
achieved regarding the relative impact of vaccine
types by host infection status required for efficacy,
PSI vaccines appeared to have a generally greater
and more rapid impact on the tuberculosis epi-
demic than PRI vaccines.
The modelling suggested targeting vaccination to
all ages, or to adults/adolescents in place of, or in
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addition to, neonatal vaccination could substan-
tially increase vaccine impact. Most studies were
set in Asia, or modelled Asia-like epidemics. Few
studies were set in Africa or included TB-HIV
coinfection.
The review highlighted several research gaps, includ-
ing the lack of studies investigating differential effects
of PRI versus PSI efficacy, age targeting of vaccines,
impact of vaccines on drug-resistant tuberculosis,
nonrandommixing of individuals or impact of chang-
ing mixing patterns on vaccine impact.
Updated systematic literature review
Search methods
We systematically searched PubMed, Embase and
the WHO Global Health Library for mathematical
modelling studies reporting the epidemiologic
impact of new human tuberculosis vaccines since
1 January 2016 using the same search terms as
Harris et al [44]. Three-stage sifting was conducted
independently by two reviewers (CKW and RAC).
We included mathematical modelling studies esti-
mating epidemiologic outcomes of TB vaccination.
We excluded studies that modelled BCG vaccines
with a single efficacy, studies that modelled the
in vitro or immunological effects of vaccination, and
reviews or commentaries that did not add new
results or analysis. The full inclusion and exclu-
sion criteria, search terms and flow diagram are
presented in the supporting information.
Experts were also consulted to identify research
aims and methods of unpublished work to identify
where research gaps may be met by upcoming
research.
We first describe the characteristics of the included
studies by summarizing the principal modelling
methods, vaccine characteristics and subgroups
(including risk groups) included in the models. We
then discuss and narratively synthesize the find-
ings of these models, grouping the studies by
comparison type. We employed the modelling study
quality and risk-of-bias appraisal tool developed by
Harris et al [44], assessing study design and
reporting against 14 criteria, for a maximum score
of 28 points.
Results
From 380 records identified through database
searches, we identified seven published studies
for inclusion. Through expert input, we also
identified two unpublished studies and one study
published after the search date. The modelled
vaccine profiles and outcomes in the eight pub-
lished papers are summarized in Table 1, and the
research aims of the unpublished studies are
briefly summarized.
Modelling methods. Seven of the eight included
studies used compartmental difference or differen-
tial equation models [10,11,45–49], whilst one
study implemented an individual-based model
[50].
Vaccine characteristics. Vaccine efficacy of
40–80% was most frequently modelled
[10,11,45–47,49,50]. Three studies modelled effi-
cacy up to 100% [11,45,48]. Most studies varied
vaccine efficacy in discrete intervals to undertake
sensitivity analyses around assumptions of vac-
cine impact [10,11,45,49,50].
Vaccines were modelled as ‘leaky’ (also known as
‘degree’) vaccines, where all vaccine recipients
receive protection proportional to the vaccine effi-
cacy, in five studies [10,11,45,46,50]; two studies
modelled vaccines assuming ‘all-or-nothing’ (also
known as ‘take’) efficacy, where all successfully
vaccinated individuals are completely protected
[48,49]. We could not determine whether the vac-
cine was degree or take in one study [46].
Vaccines providing 10 years of protection were
modelled in six studies [10,11,45,46,49,50]. Of
these, three modelled durability of greater than
10 years, including up to 40 years [46] and lifelong
[48]. One study modelled durations ranging from
2 years to lifelong [11]. One study [48] modelled
only lifelong protection, and one study modelled an
average vaccine half-life of five years [47]. Vaccine
waning was modelled as exponential decay [47] or
as ‘exact’ where all vaccine recipients lost protec-
tion at the end of the duration of protection [11].
The eight studies modelled a spectrum of host
infection status required for efficacy and preven-
tion of disease and/or infection effect. Two studies,
one modelling a POI vaccine [48] and one modelling
a POD [49] vaccine, did not specify the host
infection status required for efficacy. In contrast,
POD and POI effects were modelled in four
[10,11,45,46] that assumed PRI efficacy, four
studies that assumed PSI efficacy [10,11,45,50]
and three that assumed P&PI efficacy [10,11,45].
Two studies modelled PSI efficacy with both POD
New tuberculosis vaccines / C. K. Weerasuriya et al.
668 ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































New tuberculosis vaccines / C. K. Weerasuriya et al.
ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 669














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































New tuberculosis vaccines / C. K. Weerasuriya et al.
670 ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































New tuberculosis vaccines / C. K. Weerasuriya et al.
ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 671
Journal of Internal Medicine, 2020, 288; 661–681
and POI effects [11,47] and three studies modelled
PRI efficacy with both POD and POI effects
[11,46,47].
Vaccine deployment, setting, population and risk
groups. Eight studies implemented country-level
models, two of which were set in multiple countries
[11,47]. Three modelled Mtb transmission in China
[10,11,48], three in India [11,45,49] and two in
South Africa [11,50]. One study compared a high-
income country with low Mtb transmission (the
United States) against a lower-middle-income
country with high levels of Mtb transmission
(Cambodia) [47]. Only one study, which investi-
gated spatial targeting, modelled at a subnational
level (in the Indian state of Gujarat) [49].
All models were age-structured. Two models strat-
ified their populations by HIV status [11,50]. Both
studies modelled an increased risk of TB disease
progression and reactivation in people living with
HIV, represented antiretroviral therapy (which
reduced the impact of HIV on TB progression) and
included HIV-specific mortality rates. Shrestha
et al. also included age- and sex-specific risk of
HIV acquisition and increased risk of TB incidence
with decreasing CD4 + cell count. Both studies
assumed that new TB vaccines were effective in
HIV-positive populations, but one [11] further
varied vaccine safety and efficacy in HIV-positive
populations. In this study, vaccine protection in
HIV-positive individuals was modelled at three
levels: equal to HIV negative, 20% relative reduc-
tion in protection than HIV negative and con-
traindicated (not administered).
A single study, set in India, included a diabetes
mellitus (DM) stratum [45]. DM was modelled as
influencing TB natural history and treatment out-
comes, and the DM burden was calibrated to age-
and time-specific trends. Vaccination was targeted
solely to individuals with DM to assess the popu-
lation impact of targeting interventions to this risk
group. This study did not investigate differential
vaccine efficacy by DM status.
Heterogeneous mixing was implemented in four
studies [10,11,49,50]. Two studies implemented
age-specific contact matrices based on empirical
data for China [10,11], and one for South Africa
[11]. One study [49] investigated targeting new TB
vaccines to high incidence spatial ‘hotspots’, com-
pared with random untargeted community vacci-
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homogeneous mixing within hotspot and non-
hotspot populations, but differential mixing
between them. Differential inter-population mixing
was modelled by varying the fraction of the per
capita hazard of Mtb infection generated in each
population, which results in Mtb transmission to
members of the alternate population. One further
study [50] developed an individual-based model of
Mtb transmission in miners and their original
labour sending communities. This model investi-
gated the impact of targeted vaccination amongst
miners in comparison with random vaccination of
their originating communities. Miners were
assumed to travel to and stay at the mine whilst
employed, where they only mix with other miners;
on returning to their original communities, they
mix with nonminers.
Epidemiologic impact of future new TB vacci-
nes. Seven studies modelled new, hypothetical
vaccines [10,11,45,47–50], one of which also
included modelling of the potential impact of
adolescent BCG revaccination [11]. One study
[46] modelled the impact of discontinuing BCG
vaccination, with BCG vaccine efficacy varied dur-
ing scenario analysis. These eight studies, along
with their respective modelled vaccine profiles, are
summarized in Table 1.
Age-based vaccine targeting—Three studies com-
pared the impact of targeting vaccine delivery by
age [10,47,48].
Harris et al [10] investigated the relative impact of
targeting adolescents for vaccination compared with
older adults in China. Delivery to adolescents was
modelled as routine annual vaccination, with 70%
coverage of 15-year-olds, beginning in 2025 with an
initial catch-up campaign to 16- to 19-year-olds.
For older adults, routine vaccination was delivered
to 60-year-olds with a catch-up campaign delivered
to 61- to 64-year-olds. Due to the low-transmission,
high-relapse and reactivation-driven TB epidemic in
China, the study found that older adult targeting of
vaccination resulted in greater TB incidence rate
reduction and lower number needed to vaccinate
per case averted than adolescent targeting across all
modelled vaccine characteristics.
Liu et al [48] found that routine neonatal vaccina-
tion with a high efficacy (100%) vaccine delivered
with 95% coverage from 2018 to onwards in China
failed to achieve the ‘End TB’ incidence rate
reduction goal by 2035. In contrast, End TB goals
were achieved with a mixed targeting strategy, with
routine annual neonatal vaccination with 70%
coverage, combined with 5-yearly pulsed mass
vaccine campaigns applied to all ages with 25%
coverage. Decreased inter-pulse intervals and
increased mass campaign coverage were predicted
to achieve the End TB goals sooner, with 80%
neonatal coverage combined with 30% 3-yearly
mass campaign coverage from 2018 accomplishing
the goals by 2030.
Renardy and Kirschner [47] compared the effect of
delivering PRI-POI and PSI-POD vaccines, simul-
taneously, with two distinct age groups in a high
transmission (Cambodia) and low transmission
(the United States) setting. They found that TB
incidence in 2075 was minimized in the United
States through PRI-POI vaccination of adolescents
(aged 12–15) and PSI-POD vaccination of adults
(aged 50–70). In contrast, in Cambodia, the opti-
mal age group for PRI-POI vaccination increased to
age 22–30. Further, in the low transmission set-
ting, the age group targeted for PSI-POD vaccina-
tion was a greater determinant of vaccine impact
than the age group targeted for PRI-POI vaccina-
tion. The latter effect was attributed to a lower rate
of primary Mtb infection in the low transmission
setting. The study also found that including high
coverage routine PRI-POI neonatal vaccination in a
high transmission setting potentially reduced TB
incidence in 2075 further and shifted the optimal
age for adolescent PRI-POI vaccination upwards (to
18- to 30-year-olds).
Host infection status required for efficacy and
mechanism of effect—Three studies directly com-
pared vaccines profiles with varying host infection
status required for efficacy. One of these studies
also compared the relative impact of POI versus
POD vaccines.
In the Awad et al [45] model, PRI-POD, PSI-POD
and P&PI-POD vaccines were administered to
individuals with diabetes mellitus (DM) in India
with 50% coverage. The outcome of interest was the
number of individuals who needed to receive vac-
cination to avert a single TB case (NNVc). This
study assumed that a PRI vaccine was only admin-
istered to DM individuals without TB, whereas a
PSI vaccine was only delivered to DM individuals
with latent TB. PRI-POD vaccination of populations
with DM (conferring lifelong duration of protection,
with 60% protection against fast progression fol-
lowing infection, 50% reduction in reactivation
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from latent TB and a 50% reduction in infectious-
ness) was found to result in an NNVc of 14 by 2050.
In contrast, PSI-POD vaccination of populations
with DM (conferring lifelong duration of protection,
50% reduction in reactivation from latent TB and
60% reduction in infectiousness) was predicted to
achieve an NNVc of 25. Finally, simultaneous PRI-
POD and PSI-POD vaccination of populations with
DM was predicted to achieve an NNVc of 17.
Despite lower overall impact, PSI vaccination had
a faster epidemiologic impact.
The study of age-targeted vaccination in China by
Harris et al [10] modelled POD vaccines and
directly compared PRI-POD, PSI-POD, P&PI-POD
and a further subtype of PSI vaccination only
effective in reducing reactivation from latent TB
infection (PSI-L-POD). The study found P&PI-POD,
PSI-POD, PSI-L-POD and PRI-POD vaccination of
older adults achieved TB incidence rate reductions
in 2050 of 13.8% (uncertainty range: 12.915.2),
10.8% (UR: 10.2–11.2), 6.1% (UR: 1.3–8.7%) and
3.3% (UR: 2.3–5.3), respectively. For adolescent
vaccination, P&PI-POD and PRI-POD vaccination
led to incidence rate reductions in 2050 of 1.8%
(UR: 1.5–2.4) and 1.7% (UR: 1.4–2.3), respectively.
Adolescent PSI-POD and PSI-L-POD vaccination
had a comparatively small impact, leading to
incidence rate reductions of 0.07% (UR:
0.05–0.09) and 0.05% (UR: 0.04–0.07), respec-
tively. As above, these findings likely represent a
TB epidemic dominated by relapse-driven disease
in the elderly population, with a smaller contribu-
tion by primary Mtb infection of younger age
groups.
In a separate study, Harris et al [11] directly
compared the effect of all combinations of P&PI,
PSI and PRI against POI, POD and prevention of
infection and disease (POI&D) across China, South
Africa and India, with the latter reflecting epi-
demics with greater levels of transmission. Vacci-
nes with a POD effect were found to have the
greatest impact overall. A 10-year, 70% efficacy
PSI-POD vaccine delivered routinely to 9-year-olds,
with 10-yearly campaigns to those aged 10 and
above, was predicted to achieve incidence rate
reductions of 51% (UR: 50–51), 52% (44–58) and
54% (44–61) in China, South Africa and India,
respectively. In contrast, PSI-POI vaccination (vac-
cines which protect against reinfection) achieved
the smallest incidence rate reduction, leading to
1% (1–2), 12% (4–24) and 17% (8–31) in China,
South Africa and India, respectively. The impact of
PRI-POI and PSI-POI vaccines was intermediate
and comparable to one another. In South Africa, a
100% efficacy, 10-year P&PI-POI&D vaccine with
equal efficacy between HIV-positive and HIV-nega-
tive populations was predicted to achieve incidence
rate reductions of 84% (81–87%), falling to 79%
(72–84%) and 62% (44–74%) with a relative efficacy
reduction of 20% compared with HIV-negative
populations or contraindicated in HIV-positive
individuals, respectively.
Non-age risk group targeting—Two studies com-
pared targeting subpopulations (not based on age)
against untargeted mass vaccination.
Shrestha et al [50] compared the impact of
targeting members of a mining population with
untargeted vaccination of the originating labour
sending community. Mine-targeted vaccination
averted 1.46 (95% range: 1.13–1.91) times more
TB cases than community vaccination. The
greater impact of mine targeting was correlated
with the proportion of incident TB occurring
amongst adult men (all miners were adult men
in this model). Similarly, the study found that the
proportion of adult men in the original labour
sending community was inversely related to the
impact of mine targeting. The study concluded
that occupational targeting may be most effective
where a substantial demographic gradient of TB
incidence with a concurrent demographic gradient
by occupation exists.
In a separate study, Shrestha et al [49] compared
vaccinating high incidence spatial ‘hotspots’ of TB
with spatially untargeted vaccination in Gujarat,
India. With no mixing of individuals between
hotspots and the general population, targeting
either population led to comparable incidence rate
reductions (approximately 24% compared with no
vaccine). Vaccination of hotspots with increasing
levels of inter-population mixing was predicted to
lead to progressively higher vaccine impact. Spa-
tially targeted vaccination was predicted to be more
impactful as the relative size of TB incidence in
hotspots relative to the general population was
increased.
Health economic analyses—Fu et al [46] modelled
the cost implications of discontinuing the national
BCG programme in an intermediate burden setting
(Taiwan), varying BCG efficacy against pulmonary
and extrapulmonary TB and accounting for
decreased BCG-related side effects and increased
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TB incidence. This study found BCG discontinua-
tion to be cost-saving over all scenarios of vaccine
efficacy; the incremental cost of TB treatment
because of increased burden was small compared
with reduced costs of BCG vaccination.
Modelled time frame—The WHO/Stop TB global
targets aim to reduce TB incidence rates to 10
cases per 100 000 population per year by 2035,
and ‘eliminate’ TB by 2050 (<1 case per million
population). Liu et al [48] presented results sug-
gesting 2035 goals could be met, but assumed
vaccine introduction in 2018 and required rela-
tively frequent mass campaigns in addition to
neonatal vaccination. Five studies modelled time
horizons until at least 2050 [10,11,45–47]. Four of
these studies [10,11,45,47] projected that the
scenarios of novel vaccines and implementation
modelled may not achieve 2035 nor 2050 goals in
the countries modelled (Cambodia, South Africa,
India and China), but would likely provide an
important contribution towards reduction in inci-
dence and cases averted. One study [46] presented
outcomes not aligned with ‘End TB goals’. Two
studies specified their models in relative time,
rather than calendar time, so could not be com-
pared with WHO goals [49,50].
Modelling studies in relation to the vaccine pipeli-
ne. Only one study [46] modelled a currently in-
use vaccine (BCG). As the remaining published
studies modelled hypothetical vaccines, their
results cannot be directly mapped to the possible
epidemiologic impact of late-stage vaccine pipeline
candidates. Moreover, not all candidates in the
late-stage pipeline have been assessed across
comparable populations and implementation sce-
narios to those in the modelling studies. However,
there are broad overlaps between the known (or
under-investigation) host infection status required
for efficacy and mechanism of effect pipeline vac-
cine candidates and vaccines investigated in the
modelling studies (Table 2), with one study explic-
itly modelling vaccines with M72/AS01E and BCG
revaccination-like characteristics [11]
M72/AS01E, VPM1002, Vaccae, MIP/Immunovac
and H56:IC31 have been investigated or are under
investigation for POD effect in PSI populations
(Fig 2). Correspondingly, studies by Harris et al
[10,11], Awad et al [45], Shrestha et al [49,50] and
Renardy and Kirschner [47] have modelled the
possible impact of vaccines with PSI-POD effect.
VPM1002 is planned to be investigated for PRI-
POD efficacy, modelled by Fu et al [46], Harris
et al [11] and Awad et al [45]. Finally, PRI-POI
effect has been investigated for BCG revaccination
and DAR-901 and modelled most closely by Fu
et al [46], Renardy and Kirschner [47], Harris et al
[11] and Liu et al [48]. Finally, two unpublished
studies (below) are expected to directly model
epidemiologic impact and cost-effectiveness of
M72/AS01E or M72/AS01E-like vaccination
[51,52].
Quality appraisal. We found study quality scores
ranging from 11 to 26 out of 28, with a median
score of 23 points (Table S4). The major quality gap
was in model validation: only 1 of 8 studies [45]
was validated.
Unpublished studies. We describe two unpub-
lished studies presented as conference abstracts,
identified through expert consultation. The first
study was an age-structured dynamic transmis-
sion model, which investigates the impact and
cost-effectiveness of routine adolescent M72/
AS01E vaccination in India and South Africa [51].
This study includes stratification by HIV status in
South Africa. The second study was an age-, drug
resistance- and treatment history-stratified
dynamic transmission model, which models PRI,
PSI and P&PI vaccines with POD effect in India and
China, reporting vaccine impact on drug-resistant
tuberculosis and cost-effectiveness [52]. Both
studies explore outcomes over the 2050 time
frame.
Discussion
Since the last systematic review of the epidemio-
logic impact of TB vaccine modelling literature in
2016 [44], new studies have investigated the
differential impact of PRI versus PSI vaccines,
combinations of POI and POD effect, and age and
risk group targeting of vaccination. Whereas in the
previous review, the reason for the polarization of
outcomes for PRI versus PSI vaccines was unclear,
the new studies reviewed here suggested that PSI
versus PRI impact may be driven by the level of Mtb
transmission in the modelled epidemiologic set-
ting. Where disease incidence is driven more by
reactivation or relapse rather than new infections
with fast progression to disease, PSI vaccines were
predicted to have greater impact. This differential
impact for PRI versus PSI vaccines in recurrence-
driven settings like China becomes greater when
vaccines are age-targeted: PSI vaccines were most
impactful when delivered to older populations.
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Similarly, when both PRI and PSI vaccines were
deployed simultaneously, to adolescents and older
adults, respectively, the age group to which PSI
vaccines were targeted was the major determinant
of overall vaccine impact in a low transmission
environment (the United States). In contrast, in a
high transmission environment (Cambodia), the
major determinant was the age group to which PRI
vaccine was targeted. In the previous review, no
models had explicitly explored targeting of vacci-
nation of older adults or the elderly, an evidence
gap that has now begun to be addressed in the
literature. Finally, evidence for the value of all-age
mass campaigns as a supplement to continuous
routine neonatal vaccination has also been
strengthened.
Seven of eight studies modelled vaccines that
included POD effect [10,11,45–47,49,50], whereas
only two studies modelled a vaccine with only POI
effect [11,48]. One study [11] directly compared
POI versus POD vaccination. This study found that
PSI-POD vaccination would be likely to have a
substantially larger epidemiologic impact than
PRI-POD vaccination over the 2050 time frame,
but that PRI-POI and PSI-POI vaccination would
likely lead to intermediate impact, so POD vaccines
would provide greatest impact over the 2050 time
frame if effective in PSI populations. Finally, mod-
elling studies have begun to reflect the latest
developments in the vaccine development pipeline,
now explicitly representing M72/AS01E- and BCG
revaccination-like characteristics.
New developments include studies that investi-
gated vaccine targeting to individuals with diabetes
mellitus [45], targeting by occupation [50] and
targeting to spatial hotspots [49]. These results
suggested that targeting of risk groups may con-
tribute to efficiently reducing overall burden,
through a lower number of people needed to
vaccinate per TB case averted. It is noted that risk
group targeting has been studied only in narrow
contexts and the generalizability of these findings
across epidemiologic settings is unknown. More-
over, other epidemiologically important risk
groups, for example malnourished populations
[53], may need evaluation depending on context.
Significant research gaps persist. The only study
to investigate the impact of vaccination on drug-
resistant TB [52] remains unpublished. No new
studies investigated how vaccine impact might
interact with nonvaccine interventions such as
preventive therapy for latent Mtb infection, novel
diagnostic technologies or changes to national TB
policy, including active case finding strategies.
Few studies implemented heterogeneous mixing
other than between age groups (e.g. between
miners and nonminers, between a hotspot popu-
lation and nonhotspot populations). No studies
assessed how changing patterns of social contact
in the general population over time might affect
TB vaccine impact. Whilst we identified three new
model settings (Taiwan, Cambodia and the United
States), the remaining studies remained focused
on China, India and South Africa. Studies in
other high-burden countries, including Indonesia,
the Philippines, Pakistan, Nigeria or Bangladesh
that collectively account for 28% of global TB
burden, were lacking [1]. Moreover, only one
study investigated a subnational setting. As
implementation-related questions arise, subna-
tional models will be needed for large, heteroge-
neous countries. In the previous review, HIV
stratification was only present in four studies
and was identified as an important research gap
for exploring vaccine impact. Of two new studies
that included people living with HIV, one investi-
gated differential vaccine safety and efficacy by
HIV status. In South Africa, where HIV prevalence
is high, contraindication in HIV-positive popula-
tions was found to substantially reduce the over-
all epidemiologic impact of TB vaccination.
However, neither study investigated HIV-related
targeting. Whilst incremental progress has been
made, the impact of TB vaccines on TB-HIV
coinfection remains underexplored. One unpub-
lished study including HIV stratification investi-
gating vaccine cost-effectiveness in a high-HIV-
burden setting may contribute towards address-
ing this research need [51].
Previous modelling literature found new TB vacci-
nes to be an overwhelmingly cost-effective inter-
vention. New economic analyses were limited to
questions around BCG, and gaps remain for
assessing the full potential value of new TB vacci-
nes and for estimating the value of reducing
uncertainties around estimates of vaccine impact.
Studies have not explored differential costs of
differential routes of administration or dose regi-
mens. Finally, the range of vaccine implementation
strategies was limited, with no exploration of
country-specific delivery strategies grounded in
local capacity, strategic objectives or costs. How-
ever, cost-effectiveness analyses of new TB vacci-
nes are underway with publication anticipated.
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The key strength of this review is the conduct of
independent search, filtration, data extraction and
quality appraisal by two authors. Analysis of
study results was limited by lack of access to
underlying data, leading to crude estimates of
outcomes such as proportion immunized (if these
data were not reported). We found that the median
quality of new TB modelling studies was slightly
higher than in the previous review, possibly
reflecting continuing maturation of TB vaccine
modelling as a field.
Our findings, taken together with the results from
the systematic review by Harris et al [44] in 2016,
suggest a growing consensus amongst TB vaccine
models. Overall, Mtb transmission is driven by
pulmonary disease amongst adults, with a rela-
tively larger contribution from younger adults in
high transmission settings, for example Cambodia,
or the elderly in high reactivation settings, for
example China. Effective vaccines targeted towards
these higher burden populations are likely to
achieve a greater and more rapid epidemiologic
impact than vaccines targeted towards neonates.
As such, routine or period mass campaigns of
adolescents and/or adults may be required if End
TB targets are to be met. However, the specific
characteristics of any new vaccine, and epidemiol-
ogy within the population to which it is being
introduced, must be factored into targeting and
deployment strategies. If multiple vaccine candi-
dates with differing characteristics (e.g. PRI vs PSI
efficacy) are successfully developed, mixed vacci-
nation strategies targeting differing groups may be
appropriate depending on the specific epidemiol-
ogy of the target setting. Previous work has found
adult and adolescent tuberculosis vaccination to
likely be overwhelmingly cost-effective. Whilst no
further cost-effectiveness analyses have been pub-
lished, the epidemiological evidence now suggests
that targeting to (context-specific) risk groups may
be more efficient in terms of number needed to
vaccinate per case averted. The cost-effectiveness
of such targeting strategies must be explored to
inform optimal implementation strategies. Evi-
dence for the impact of vaccines on other cost
drivers, such as drug-resistant tuberculosis, needs
further exploration and is upcoming. Overall, the
implementation aspects of TB vaccine delivery
remain underexplored. As there is little precedent
for large-scale adolescent and adult vaccination in
the order likely required for TB control, and as
Table 2. Overlap between known or under-investigation host status required for efficacy and mechanism of effect in late-




revaccination DAR-901 H56:IC31 M72/AS01E
MIP/
mmunovac Vaccae VPM1002
PRI-POI PRI-POI PSI-POD PSI-POD PSI-POD PSI-POD
PRI-POD
PSI-POD
Shrestha et al. [49] a a a a a
Liu et al. [46] a a
Shrestha et al. [50] a a a a a
Fu et al. [46] a a a
Renardy and
Kirschner [47]
a a a a a a a
Harris et al. [10] a a a a a
Awad et al. [45] a a a a a
Harris et al. [11] a a a a a a a
Harris et al.
(unpublished) [51]
a a a a a
Weerasuriya et al.
(unpublished) [52]
a a a a a
aIndicates that a vaccine candidate (column) had characteristics overlapping with a vaccine profile investigated in a
modelling study (row). Overlap in vaccine efficacy and duration of protection are not shown.
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candidates progress towards licensure, such stud-
ies will become increasingly important to inform
decision-making.
Concluding remarks and future directions
We have identified critical priorities for M72/AS01E
and BCG revaccination, for other late-stage candi-
dates, for modelling and for the field as a whole.
A larger confirmatory M72/AS01E trial, currently
in-design, should be powered to improve the pre-
cision of efficacy estimates, include uninfected
populations and further assess safety and
immunogenicity in HIV-infected people. Further
investigations will need to explore protection in
other high-risk groups and the duration of vaccine
protection. Results from multiple geographical
settings may be required to generalize findings.
Investments are needed not only for the next phase
of clinical trials, but also to ensure sustainable and
affordable supply of vaccine antigens and adju-
vant. Preparatory work on licensure and policy
pathways, equitable access and delivery should be
initiated early to allow rapid implementation,
should phase III trial results be positive.
For BCG revaccination, the priority is completing
the ongoing confirmation of efficacy trial to esti-
mate vaccine efficacy with more precision, as the
original confidence intervals were wide [5]. Further
trials are likely to be needed to explore efficacy
against disease. Even if confirmed, obstacles to
BCG delivery would include its current contraindi-
cation for people living with HIV. Support for other
candidates should continue in case BCG revacci-
nation or M72/AS01E do not succeed, and to
ensure a pipeline of next-generation vaccines.
Samples from the two recent efficacy trials [5,6] are
being examined to identify mechanisms and corre-
lates of protection, which should lead to a better
understanding of protective immunity against TB.
This, in turn, should guide future vaccine discov-
ery and accelerate the clinical testing of candi-
dates. Trials incorporating other important risk
groups, such as the elderly, patients with diabetes
or pregnant women, will become important as
candidates advance towards the end of the devel-
opment pipeline.
Tuberculosis vaccine modelling has produced use-
ful new insights over the past four years, by
exploring the differential impact of vaccine
characteristics, age targeting, spatial or risk group
targeting and accounting for drug-resistant TB.
Future models should generate evidence on the full
value proposition of TB vaccines including com-
parison with other interventions, more realistic
implementation strategies including vaccine tar-
geting, and estimating the value of information to
reduce uncertainties about BCG revaccination and
M72/AS01E impact.
The TB vaccine field needs to progress strategi-
cally. An increase and diversification of resources
is required because currently available funding for
TB vaccines [54] is insufficient. Allocation of these
resources should include the discovery and devel-
opment of early pipeline candidates and increasing
clinical trial capacity.
Finally, we must prepare now for the prompt and
equitable implementation of a successful new
vaccine, so that the benefits are felt quickly by
people most in need.
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adults boosted with an inactivated whole-cell mycobacterial
vaccine. AIDS 2010; 24: 675–85.
30 Munseri P, Said J, Amour M et al. DAR-901 vaccine for the
prevention of infection with Mycobacterium tuberculosis
among BCG-immunized adolescents in Tanzania: A random-
ized controlled, double-blind phase 2b trial. Vaccine 2020;
38: 7239–45.
31 Bill & Melinda Gates Medical Research Institute. A Random-
ized, Placebo Controlled, Observer-Blind, Phase IIb Study to
Evaluate the Efficacy, Safety, and Immunogenicity of BCG
Revaccination in Healthy Adolescents for the Prevention of
Sustained Infection With Mycobacterium Tuberculosis. clin-
icaltrials.gov; 2020. Report No.: NCT04152161. Available
New tuberculosis vaccines / C. K. Weerasuriya et al.
ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine 679
Journal of Internal Medicine, 2020, 288; 661–681
from: https://clinicaltrials.gov/ct2/show/NCT04152161.
(Accessed 2020 Jun 25)
32 World Health Organization. M72/AS01E vaccine candidate
consensus generating consultation on the development path-
way. Geneva: Switzerland, 2019. Available from: https://
www.who.int/publications/m/item/m72-as01e-tuberculo
sis-vaccine-candidate.
33 World Health Organization. Report of the high-level consulta-
tion on accelerating the development of the M72/AS01E
tuberculosis vaccine candidate. Geneva, Switzerland: World
Health Organization, 2019. Available from: http://origin.
who.int/tb/areas-of-work/research/meeting_report_m72_
vaccine.pdf. (Accessed 2020 Jun 28)
34 Phase III Clinical Study of Efficacy and Safety of VaccaeTM to
Prevent Tuberculosis. Available from: https://clinicaltrials.
gov/ct2/show/NCT01979900. (Accessed 2020 Jun 28)
35 Nieuwenhuizen NE, Kulkarni PS, Shaligram U et al. The
Recombinant Bacille Calmette-Guérin Vaccine VPM1002:
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